Background Metabolic syndrome (MS) has an increased risk for developing cardiovascular disease (CVD); however, whether the concept of MS, applying the new joint interim statement definition, has a greater impact on incident CVD than its individual components is debated.
Methods The authors related MS and its components to CVD incidence in 1856 men and 2392 women, Iranian adults aged ≥40 years, free of CVD at baseline, using Cox proportional hazards models. To examine whether MS would improve prediction of CVD beyond that achieved by its components; model fitness, discrimination and integrated discrimination improvement (IDI) statistics were used.
Results During a median follow-up of 8.6 years, there were 244 CVD events in men and 189 in women. MS resulted in HRs (95% CIs) of 1.97 (1.50 to 2.57) in men and 2.25 (1.57 to 3.21) in women after adjusting for CVD risk factors; in another model including all the five MS components, high blood pressure in both genders [men: 1.99 (1.48 to 2.67), women: 1.62 (1.14 to 2.30)), high waist circumference (≥94.5 cm) in men (1.47 (1.12 to 1.93)) and high fasting plasma glucose (FPG) in women (1.88 (1.39 to 2.55)) remained as independent predictors of CVD after adjusting for CVD risk factors. Adding the MS variable to this model did not yield any improvement in model fitness, C-statistic or significant IDI value.
Conclusion In the Middle East population, MS did not provide CVD predictive risk information beyond its individual components; clinical focus should remain on hypertension in both sexes, high FPG in women and central adiposity in men rather than MS.
- Metabolic syndrome
- cardiovascular disease
- cardiovascular risk factors
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This study was supported by Grant No 121 from the National Research Council of the Islamic Republic of Iran.
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics approval was provided by the The Ethical Committee of the Research Institute for Endocrine Sciences.
Provenance and peer review Not commissioned; externally peer reviewed.